Cite
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group.
MLA
Walter-Croneck, Adam, et al. “Case-Adjusted Bortezomib-Based Strategy in Routine Therapy of Relapsed/Refractory Multiple Myeloma Shown to Be Highly Effective—A Report by Polish Myeloma Study Group.” Leukemia Research, vol. 38, no. 7, July 2014, pp. 788–94. EBSCOhost, https://doi.org/10.1016/j.leukres.2014.04.011.
APA
Walter-Croneck, A., Grzasko, N., Soroka-Wojtaszko, M., Jurczyszyn, A., Torosian, T., Rymko, M., Nowicki, A., Druzd-Sitek, A., Lech-Maranda, E., Madro, E., Zielinska, P., Grygoruk-Wisniowska, I., Blonska, D., Usnarska-Zubkiewicz, L., Potoczek, S., Iskierka, E., Masternak, A., Holojda, J., Dawidowska, D., & Gawron, L. (2014). Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective—A report by Polish Myeloma Study Group. Leukemia Research, 38(7), 788–794. https://doi.org/10.1016/j.leukres.2014.04.011
Chicago
Walter-Croneck, Adam, Norbert Grzasko, Maria Soroka-Wojtaszko, Artur Jurczyszyn, Tigran Torosian, Marcin Rymko, Adam Nowicki, et al. 2014. “Case-Adjusted Bortezomib-Based Strategy in Routine Therapy of Relapsed/Refractory Multiple Myeloma Shown to Be Highly Effective—A Report by Polish Myeloma Study Group.” Leukemia Research 38 (7): 788–94. doi:10.1016/j.leukres.2014.04.011.